arrow
E

Eric A. Ross

department of biostatistics
H指数:60
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial
2024-10-011
PRE
A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery

一项评估择期大癌症手术后围手术期风险分层和基于风险的协议驱动管理的随机对照试验

2024-07-240
PRE
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

卡铂,培美曲塞和贝伐单抗联合或不联合阿特珠单抗治疗具有敏感EGFR突变或从未吸烟的IV期非鳞状非小细胞肺癌患者的II期随机试验

2023-11-010
PRE
Emi1 Maintains Genomic Integrity during Zebrafish Embryogenesis and Cooperates with p53 in Tumor Suppression

Emi1在斑马鱼胚胎发生过程中维持基因组完整性,并与p53协同抑制肿瘤

2023-03-2132
OAAI
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy

Guadecitabine联合Atezolizumab治疗初始免疫检查点抑制剂治疗后进展的转移性尿路上皮癌的II期试验

2023-03-1617
OAAI
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine

癌症患者服用2剂mRNA新型冠状病毒肺炎疫苗后报告的不良事件

2022-02-0114
OA
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)

比卡鲁胺联合或不联合二甲双胍治疗超重或肥胖前列腺癌患者生化复发的随机2期研究 (BIMET-1)

2022-01-2517
OAAI